Clinical study manager: Charlois-Ou C. Other members: Bouscambert Invited members (informed of study design but did not participate in any decision-making study discussions; supplied drugs and placebos), Steering committee: Leport C Gysembergh-Houal A (AP-HP) ,
Monitoring and statistical analysis Studypharm clinical research organisations Clinical investigators, Independent data-monitoring committee ,
Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis, The Lancet Infectious Diseases, vol.9, issue.9, pp.537-545, 2009. ,
DOI : 10.1016/S1473-3099(09)70199-9
Efficacy and Safety of the Neuraminidase Inhibitor Zanamivir in the Treatment of Influenzavirus Infections, New England Journal of Medicine, vol.337, issue.13, pp.874-880, 1997. ,
DOI : 10.1056/NEJM199709253371302
Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial, Neuraminidase Inhibitor Flu Treatment Investigator Group, pp.1845-1850, 2000. ,
DOI : 10.1016/S0140-6736(00)02288-1
Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza, JAMA, vol.283, issue.8, pp.1016-1024, 2000. ,
DOI : 10.1001/jama.283.8.1016
Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis, BMJ, vol.339, issue.dec07 2, p.5106, 2009. ,
DOI : 10.1136/bmj.b5106
Zanamivir: a Significant Reduction in Viral Load During Treatment in Military Conscripts with Influenza, Scandinavian Journal of Infectious Diseases, vol.35, issue.1, pp.52-58, 2003. ,
DOI : 10.1080/0036554021000026981
Influenza Virus Resistance to Antiviral Agents: A Plea for Rational Use, Clinical Infectious Diseases, vol.48, issue.9, pp.1254-1256, 2009. ,
DOI : 10.1086/598989
Hedging against Antiviral Resistance during the Next Influenza Pandemic Using Small Stockpiles of an Alternative Chemotherapy, PLoS Medicine, vol.312, issue.5, 2009. ,
DOI : 10.1371/journal.pmed.1000085.s005
Surveillance for Neuraminidase Inhibitor Resistance among Human Influenza A and B Viruses Circulating Worldwide from 2004 to 2008, Antimicrobial Agents and Chemotherapy, vol.52, issue.9, pp.3284-3292, 2004. ,
DOI : 10.1128/AAC.00555-08
Emergence of a novel swine-origin influenza A (H1N1) virus in humans, N Engl J Med, vol.360, pp.2605-2615, 2009. ,
Development of a quantitative assay for SARS coronavirus and correlation of GAPDH mRNA with SARS coronavirus in clinical specimens, Journal of Clinical Pathology, vol.58, issue.3, pp.276-280, 2005. ,
DOI : 10.1136/jcp.2004.016592
Pandemic A(H1N1)2009 influenza virus detection by real time RT-PCR : is viral quantification useful?, Clinical Microbiology and Infection, vol.16, issue.4, pp.317-321, 2010. ,
DOI : 10.1111/j.1469-0691.2010.03169.x
Use of the Oral Neuraminidase Inhibitor Oseltamivir in Experimental Human Influenza, JAMA, vol.282, issue.13, pp.1240-1246, 1999. ,
DOI : 10.1001/jama.282.13.1240
Influenza virus neuraminidase inhibitors, The Lancet, vol.355, issue.9206, pp.827-835, 2000. ,
DOI : 10.1016/S0140-6736(99)11433-8
Triple Combination of Amantadine, Ribavirin, and Oseltamivir Is Highly Active and Synergistic against Drug Resistant Influenza Virus Strains In Vitro, PLoS ONE, vol.348, issue.2, 2010. ,
DOI : 10.1371/journal.pone.0009332.s006
The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design, Nature, vol.232, issue.7107, pp.45-49, 2006. ,
DOI : 10.1107/S0108767390010224
Influenza virus susceptibility and resistance to oseltamivir, Antivir Ther, vol.12, pp.603-616, 2007. ,
Selection of Influenza Virus Mutants in Experimentally Infected Volunteers Treated with Oseltamivir, The Journal of Infectious Diseases, vol.183, issue.4, pp.523-531, 2001. ,
DOI : 10.1086/318537
Neuraminidase Inhibitor Resistance after Oseltamivir Treatment of Acute Influenza A and B in Children, Clinical Infectious Diseases, vol.48, issue.4, pp.389-396, 2009. ,
DOI : 10.1086/596311